Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 10/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16037546 | 0.88 | CDK8 (0.52) | CDK8GCK | |
| SCHEMBL16038768 | 0.86 | CDK8 (0.48) | CDK8GCK | |
| SCHEMBL16038344 | 0.86 | GCK (0.49) | CDK8GCK | |
| SCHEMBL16039016 | 0.86 | CDK8 (0.48) | CDK8GCK | |
| SCHEMBL14742495 | 0.85 | GCK (0.56) | MAPK14GCKMAPK13BRAF | |
| SCHEMBL16036682 | 0.84 | KDR (0.56) | METBRAF | |
| SCHEMBL24968099 | 0.81 | PIK3C3 (0.49) | MAPK14GCKMAPK13 | |
| SCHEMBL16038073 | 0.81 | CSF1R (0.46) | MAPK14GCKMAPK13MET | |
| SCHEMBL28933414 | 0.81 | MAPK14 (0.59) | MAPK14GCKMAPK13BRAF | |
| SCHEMBL16038146 | 0.81 | KDR (0.47) | CDK8MAPK14GCKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145029-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145029-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | CDK8 160/4885MAPK14 425/4885GCK 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.